Merck & Co.’s first-in-class HIF-2 alpha inhibitor Welireg is touching down in the clear cell renal cell carcinoma (ccRCC) | ...
South Korea's Penetrium Bioscience said Wednesday that the company would start a clinical test combining its investigational ...
Merck (MRK) stock is in focus as the FDA approves a label expansion for the company's kidney cancer drug Welireg with its ...
On Monday, Gilead Sciences Inc. GILD and Merck & Co. Inc. MRK on Monday discontinued the Phase 3 KEYNOTE-D46/EVOKE-03 trial ...
16don MSN
‘King Keytruda’s reign continues.’ Investors aren’t wowed by a promising new lung cancer drug
The highly anticipated study found that ivonescimab reduced the risk of death by 34% compared with another drug ...
Merck & Co.’s Keytruda has become the first immunotherapy approved by the FDA to be used around surgery to treat resectable locally advanced head and neck cancer. But the breakthrough approval comes ...
Researchers found that Keytruda — the focus of ICIJ's recent Cancer Calculus investigation — accounted for nearly half of the ...
Add Yahoo as a preferred source to see more of our stories on Google. This story was originally published on BioPharma Dive. To receive daily news and insights, subscribe to our free daily BioPharma ...
Adding Keytruda to chemotherapy with or without radiotherapy did not improve disease-free survival in newly diagnosed high-risk endometrial cancer. The phase 3 KEYNOTE-B21 clinical trial, evaluating ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results